AIM ImmunoTech (AIM) Q4 2025 earnings summary

Executive summary

• Focused on developing Ampligen for late-stage pancreatic cancer, with ongoing and planned clinical trials, and continued R&D in immuno-oncology and antiviral applications.

• Ampligen is approved for severe CFS in Argentina but not in the U.S.; Alferon N Injection is FDA-approved for genital warts but not currently manufactured.

• Company faces significant liquidity challenges, recurring losses, and a working capital deficit, raising substantial doubt about its ability to continue as a going concern.

• Regained NYSE American compliance after a reverse stock split, but must increase stockholders' equity to maintain listing.

Financial highlights

• Net loss for 2025 was $13.96 million, a 19% improvement from $17.32 million in 2024, mainly due to reduced G&A and R&D expenses.

• Revenues from Ampligen Cost Recovery Program were $88,000 in 2025, down from $170,000 in 2024.

• Cash and equivalents at year-end 2025 were $3.05 million, down $930,000 from 2024.

• Stockholders' deficit at year-end 2025 was $9.78 million.

• No material revenue is expected in the near future; additional funding will be required.

Outlook and guidance

• Ongoing focus on Ampligen for pancreatic cancer, with a Phase 3 trial in planning and continued enrollment in the DURIPANC Phase 2 study.

• Plans to seek additional capital through securities offerings and warrant exercises.

• If unable to raise sufficient capital or regain compliance, risk of delisting from NYSE American remains.